Immutep Ltd - Asset Resilience Ratio

Latest as of June 2025: 50.67%

Immutep Ltd (IMM) has an Asset Resilience Ratio of 50.67% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Immutep Ltd (IMM) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$79.54 Million
≈ $56.28 Million USD Cash + Short-term Investments

Total Assets

AU$156.98 Million
≈ $111.08 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Immutep Ltd's Asset Resilience Ratio has changed over time. See Immutep Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Immutep Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Immutep Ltd (IMM) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$17.26 Million 10.99%
Short-term Investments AU$62.28 Million 39.68%
Total Liquid Assets AU$79.54 Million 50.67%

Asset Resilience Insights

  • Very High Liquidity: Immutep Ltd maintains exceptional liquid asset reserves at 50.67% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Immutep Ltd Industry Peers by Asset Resilience Ratio

Compare Immutep Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 1.39%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shanghai Shen Lian Biomedical Corp
SHG:688098
Biotechnology 3.87%

Annual Asset Resilience Ratio for Immutep Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Immutep Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 50.67% AU$79.54 Million
≈ $56.28 Million
AU$156.98 Million
≈ $111.08 Million
+7.54pp
2024-06-30 43.13% AU$86.94 Million
≈ $61.52 Million
AU$201.58 Million
≈ $142.63 Million
+40.70pp
2023-06-30 2.43% AU$3.59 Million
≈ $2.54 Million
AU$147.45 Million
≈ $104.33 Million
+2.14pp
2022-06-30 0.30% AU$302.00K
≈ $213.68K
AU$102.17 Million
≈ $72.29 Million
-9.80pp
2021-06-30 10.10% AU$8.28 Million
≈ $5.86 Million
AU$82.03 Million
≈ $58.04 Million
-18.94pp
2020-06-30 29.03% AU$13.53 Million
≈ $9.57 Million
AU$46.60 Million
≈ $32.97 Million
-6.43pp
2014-06-30 35.46% AU$9.00 Million
≈ $6.37 Million
AU$25.38 Million
≈ $17.96 Million
+11.08pp
2013-06-30 24.38% AU$8.00 Million
≈ $5.66 Million
AU$32.81 Million
≈ $23.22 Million
-26.19pp
2012-06-30 50.57% AU$21.05 Million
≈ $14.89 Million
AU$41.61 Million
≈ $29.44 Million
+33.23pp
2011-06-30 17.35% AU$10.00 Million
≈ $7.08 Million
AU$57.64 Million
≈ $40.78 Million
-35.25pp
2010-06-30 52.60% AU$10.00 Million
≈ $7.08 Million
AU$19.01 Million
≈ $13.45 Million
+40.53pp
2007-06-30 12.07% AU$526.17K
≈ $372.30K
AU$4.36 Million
≈ $3.08 Million
-28.43pp
2006-06-30 40.50% AU$2.98 Million
≈ $2.11 Million
AU$7.36 Million
≈ $5.21 Million
-39.77pp
2005-06-30 80.28% AU$7.33 Million
≈ $5.19 Million
AU$9.13 Million
≈ $6.46 Million
+79.93pp
2004-06-30 0.35% AU$20.00K
≈ $14.15K
AU$5.77 Million
≈ $4.08 Million
-0.83pp
2001-06-30 1.18% AU$50.00K
≈ $35.38K
AU$4.24 Million
≈ $3.00 Million
--
pp = percentage points

About Immutep Ltd

AU:IMM Australia Biotechnology
Market Cap
$62.49 Million
AU$88.32 Million AUD
Market Cap Rank
#21016 Global
#733 in Australia
Share Price
AU$0.06
Change (1 day)
-6.25%
52-Week Range
AU$0.04 - AU$0.46
All Time High
AU$0.68
About

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more